Citi lifts GSK target price but keeps neutral stance after rally Proactive uses images sourced from Shutterstock Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving investor sentiment. The broker said full-year 2025 earnings per share were 2% ahead of consensus, with constant exchange rate guidance for 2026 broadly in line with expectations. Citi trimmed its 2026 and 2027 earnings forecasts by 1% to 2% ...

February session to highlight how Zomedica's R&D strategy supports scalable growth and long-term shareholder value ANN ARBOR, MI / ACCESS Newswire / February 5, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative diagnostic and therapeutic devices for equine and companion animals, today announced the next installment of its "Fourth Friday at Four" investor webinar series, scheduled for Friday, February 27, 2026 at 4:00 p.m. Eastern Time. ...

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.Healthcare stocks are not known for healthy dividends. Great for growth, yes, but often so-so for dividend yields. The average medical large-cap stock's dividend yield was 1.67% at the end of 2025, sixth among the 11 sectors for large-cap stocks.Unlike utilities, which can rely on steady, fixed revenue sources, healthcare companies must continually invest in research an ...

Sanofi (NasdaqGS:SNY) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsBen Jackson - VP of Equity ResearchBrian Foard - EVP and Head of Specialty CareDavid Reed Risinger - Senior Managing DirectorFrançois-Xavier Roger - CFOGraham Parry - Managing Director and Head of European Pharmaceuticals Equity researchHouman Ashrafian - EVP and Head of Research and DevelopmentJames Gordon - Director and Head of European Pharma, Biotech & Life Sciences Equity ResearchJames Quigley - Executive Direc ...

Core Insights - Planet Labs (PL) emphasizes research and development (R&D) as a key driver of long-term growth and competitiveness, operating the largest fleet of Earth-observation satellites globally [1] R&D Investment - R&D expenses are classified as costs related to advancing technology, platform development, and new product iterations, accounting for 41% of revenues in fiscal 2025 [2][9] - Continuous innovation in satellite hardware, launch cadence, data infrastructure, and analytics software is essential for maintaining competitive advantage [3] - R&D spending is expected to increase, enhancing product differentiation and pricing power while lowering unit costs and extending satellite lifetimes [4][5] Competitive Landscape - R&D is crucial for the long-term competitiveness of peers like Rocket Lab (RKLB) and BlackSky Technology (BKSY), with Rocket Lab focusing on launch reliability and next-gen vehicles, and BlackSky enhancing imaging and analytics capabilities [6][7] Financial Performance - PL's stock has gained 494.2% over the past year, outperforming the industry [8] - The stock is currently overvalued, trading at a price-to-sales multiple of 22.16, significantly higher than the industry average of 2.39 [10] Earnings Estimates - There has been no movement in the Zacks Consensus Estimate for PL's fiscal fourth-quarter 2026 and fiscal first-quarter 2027 EPS over the last 30 days, with estimates indicating year-over-year increases for fiscal 2026 and 2027 [11][12]

Core Viewpoint - Amphastar Pharmaceuticals is transitioning towards higher-value proprietary products while maintaining a focus on internal development and strategic acquisitions to enhance growth and profitability [2][5][13]. Growth Strategy - The company's growth strategy is two-pronged: internal development and strategic acquisitions, including the transformative acquisition of Baqsimi and prior acquisitions like the Armstrong facility [1][3]. - Amphastar aims for a 50% proprietary product mix by 2026, shifting from a historical pipeline that was 63% generic [5][6]. Product Development and Pipeline - The company is advancing a peptide pipeline with several promising candidates, including AMP-007 (metered-dose inhaler) expected to launch in mid-2026 and AMP-004 (insulin aspart) projected for 2027 [4][10]. - Four new chemical entities (NCEs) are in development, showing promising preclinical or early clinical data [4][8]. Financial Projections - Peak sales guidance for Baqsimi is set at $250–$275 million, with expectations of mid-single-digit growth this year [3][14]. - The company plans to exit unprofitable international markets to improve margins and forecasts high single-digit growth for Primatene Mist [3][15]. Research and Development Focus - Amphastar consistently invests $60–$75 million annually in R&D, focusing on proprietary programs, including AMP-105 and AMP-107, which target significant market opportunities [8][12]. - The company is evolving its pipeline in response to increased competition in complex generics, aiming for a mix of 50% proprietary, 35% biosimilar, and 15% generic by 2026 [6][20]. Market Position and Competitive Advantage - The acquisition of Baqsimi has strengthened Amphastar's position in the proprietary commercial Rx market and expanded its international footprint [13][18]. - The company has captured a majority of the prescription market for ready-to-use glucagon and is focused on increasing penetration among insulin users [18][19].

Core Insights - Merit Medical Systems, Inc. (MMSI) is positioned for growth due to a strong product portfolio and solid performance in 2025, despite facing macroeconomic headwinds and forex volatility [2] - The company has experienced a 9% decline in shares this year, while the industry has grown by 12.5% and the S&P 500 has increased by 18.3% [2] Company Performance - Merit Medical has a market capitalization of $5.2 billion and projects a 9.6% growth rate over the next five years, with an average earnings surprise of 14.09% over the past four quarters [3] - The third quarter saw a 7.8% organic constant-currency growth, driven by strong performance in the Cardiovascular segment, particularly in Peripheral and Cardiac Intervention franchises [5][9] Positive Drivers - The demand for embolics like Embosphere and QuadraSphere remains robust, with balanced growth across the U.S., EMEA, and APAC regions, reducing dependence on any single market [6] - The gross margin reached a record 53.6%, with a 267-basis-point year-over-year expansion attributed to favorable product mix, pricing discipline, and improved distribution costs [10] - The company generated $52.5 million in quarterly free cash flow, up 38% year over year, while continuing to invest in R&D and acquisitions [10] Growth Catalysts - WRAPSODY CIE is gaining traction post NTAP reimbursement, with early adoption tracking ahead of expectations, which could significantly expand the addressable market [11][12] - The potential approval of Transitional Pass-Through (TPT) reimbursement for outpatient procedures could further accelerate WRAPSODY CIE's revenue growth [12] Key Challenges - Tariff-related costs could impact earnings significantly, with estimates ranging from $7.6 million to $16 million in 2025, depending on global trade policy developments [13] - Sales in China declined by 1% year over year, reflecting broader macroeconomic weakness, while OEM demand remains volatile, affecting revenue predictability [15][16] - Integration challenges from ongoing acquisitions could pose risks to near-term performance, particularly in the Endoscopy segment [17][18] Estimate Trends - The Zacks Consensus Estimate for earnings per share (EPS) for 2025 has increased by 4 cents to $3.73, with fourth-quarter 2025 revenue estimates at $387.5 million, indicating a 9.1% rise from the previous year [19]

Some of the wealthiest individuals in tech have pledged as much as $1 billion to CERN to fund a proposed successor to the Large Hadron Collider, as the research institute turns to private backers to back future breakthroughs https://t.co/Dv8JNGYUGb ...

Core Insights - The aerospace and defense sector is facing challenges due to potential executive orders that may impose penalties on defense primes, making profitability difficult given current operating margins of 10% and cash margins of 5% [2][4] - The balance between research and development (R&D) investment and shareholder returns is highlighted, with defense primes investing approximately $40 billion in R&D and capital expenditures while returning $50 billion through dividends and buybacks, indicating a 1.3% investment to return ratio [4][5] - The commercial aerospace market is projected to grow, with aircraft needs increasing by 3% and aftermarket services by 8-10%, making companies like GE and RTX attractive investments [7][8] Investment Dynamics - The lack of clarity in defense budgets complicates investment cycles for defense primes, which do not have 5-year budgets, impacting their ability to generate returns [8][9] - International growth is seen as a significant upside, with NATO spending potentially increasing from 2% to 3.5%, translating to $280 billion in investments for defense primes, benefiting both U.S. and European contractors [10][11] - RTX has a notable exposure to European spending, with 44% of its defense backlog linked to this market, indicating strong international growth potential [11] Geopolitical Influence - The current geopolitical climate, including U.S. defense budgets growing by 3-5%, is influencing the defense sector, with international sales typically yielding higher margins for American defense primes [10][13] - The Trump administration's support for both large and small contractors has led to increased funding and innovation within the defense sector, resulting in a rise in defense tech IPOs [14][15] - The global threat environment is broadening the focus for defense contractors beyond traditional regions, emphasizing the need for a diverse playbook to address various geopolitical challenges [15]

R&D Leadership and Organization - Sanofi is building a skilled and thoughtful R&D leadership team and organization[5, 6, 7, 106] - The company is strengthening capabilities across research, translational medicines, development, medical, regulatory affairs, and digital[106] Pipeline Highlights and Approvals - Sanofi achieved three new medicine and vaccine approvals in 2025: Qfitlia, Wayrilz, and Nuvaxovid[12, 13, 106] - Dupixent showed benefit across relevant endpoints in Bullous pemphigoid, with 12.2% difference in patients achieving sustained remission compared to placebo + OCS and 27.8% difference in patients with ≥4-point improvement in PP-NRS[20, 21] - Dupixent clinically meaningfully improved radiographic, endoscopic, and symptoms of Allergic fungal rhinosinusitis, with lower proportion of patients receiving SCS treatment and/or surgery[24] - Amlitelimab (OX40L mAb) in AD: first phase 3 study met primary and key secondary endpoints, showing clinically meaningful improvement in skin clearance and disease severity[26] - Brivekimig (TNFaxOX40L Nanobody®) in HS: phase 2a study achieved primary objective, with 54% of participants achieving HiSCR75[28, 29] - Itepekimab (IL33 mAb) in COPD: AERIFY-1 study showed a significant reduction in moderate or severe exacerbations of 27.1% at Week 52 with Q2W dosing across EOS level[38] - Duvakitug (TL1A mAb) in CD/UC: positive and encouraging phase 2b data presented at ECCO 2025, with 48% clinical remission in Crohn's disease high dose group[46, 47] - Fluzone HD demonstrated superior protection vs standard-dose influenza vaccines against hospitalization in older adults, including a -31.9% reduction in laboratory confirmed influenza hospitalization[75] - Monovalent RSV (mRNA) vaccine showed 74.9% efficacy against RSV LRTD in a phase 2 study[80] Pipeline Replenishment and Digital Transformation - Sanofi is progressing on pipeline entries augmented by strategic business development[107] - The R&D digital plan aims at reducing cycle times across the R&D value chain by more than 40%[94, 95, 107] Upcoming News Flow - Sanofi anticipates >15 regulatory decisions, >30 regulatory submissions, and >15 phase 3 data readouts in 2026 and 2027[108]